Henan belt procurement fell by a maximum of 98.91%, multinational pharmaceutical companies wiped out the whole army!

Pharmaceutical Network January 25 - January 22, Henan Province Public Resources Trading Center officially registered the "on the announcement of Henan Province's drug concentration belt procurement results of the notice."
Earlier, the province's drug supplies centralized procurement and use of the press conference revealed that, according to the results of the current round of centralized drug procurement bid, 29 drugs all successfully bid, the average decline of 70.71 percent, the highest reduction of 98.91 percent;
, however, compared with the original shortlist, Hanyu Pharmaceutical's table soft star is not in the final list of selected varieties.
it is worth noting that further combing can be found that the enterprises selected in Henan are divided into group B of local enterprises, multinational pharmaceutical companies have not been selected.
Comprehensive review gradually into the provincial collection mainstream last November, Henan officially released the "Henan Province drug centralized band procurement documents", the scope of collection involving omeprazole, table jubby star, Sichuan, Gissytabin, Lansolazine, naquoheparin sodium, curklutin, bromine has been new and niacinamide and other 29 clinically commonly used large varieties.
from the dosage form, except that the compound glyphosate and reberazole are oral normal release dosage forms, the remaining 27 are injection varieties.
or because of the related varieties related to the larger market, according to Henan issued "on the publicity of our province's drug centralized belt procurement related qualification expert review results notice", this round of collection attracted 252 pharmaceutical companies to participate, of which 241 pharmaceutical companies through the declaration requirements, AstraZeneca, Fessen Yuscabi, China Resources Shuanghe, Beijing Four Rings Pharmaceuticals, North China Pharmaceuticals, Pfizer, Jiangsu Hengrui, Jichuan Pharmaceuticals, Jiangsu Haosen and other well-known pharmaceutical companies at home and abroad.
In the selection of bidding mode, Henan is using the provincial volume procurement mainstream comprehensive evaluation method: economic and technical standard score accounted for 60%, business bid score accounted for 40%, the two scores add up to determine the final winning enterprise.
And in the group of bidding pharmaceutical companies, Henan listed the original research drugs, the evaluation of the quality and efficacy of generic drugs, according to the new registration classification of generic drugs and drugs included in the "China Listed Drugs List" as Group A, other drugs are listed as Group B.
, Henan also made it clear that varieties that meet the conditions of Group A may be voluntarily declared and included in Group B.
in the industry, bidding pharmaceutical companies according to the quality of the product level grouping, will have a greater impact on the final bidding pattern and results.
the above-mentioned enterprise qualification assessment results can be found that the division of enterprises in Group A is few.
in addition to Gixitabin has been evaluated pharmaceutical enterprises Jiangsu Howson and the original research drug company Lilly, the rest of the varieties are only one pharmaceutical enterprises into the group.
henan clearly, the number of declared enterprises is 1 or 2, will take the form of bargaining negotiations to determine the proposed enterprises.
And the decline in the price quotations for negotiated drugs is not less than the average decrease of all the drugs to be selected by the comprehensive evaluation team or the average decrease of all the drugs to be selected by the comprehensive evaluation team with the same variety of drugs, it will be determined as the enterprise to be selected, which may be the main reason why the multinational pharmaceutical enterprises collectively abstained by zero points.
multinational pharmaceutical enterprises show two strategic trends under the normalized and institutionalized command baton of volume procurement, and the exploration of provincial volume procurement and cross-regional alliance procurement continues to deepen.
from the past harvest results, the active price reduction should be selected enterprises are still the mainstream of local pharmaceutical companies, multinational pharmaceutical companies more out of the maintenance of brand prices and choose to withdraw from the collection market melee.
But with the volume of procurement, health insurance fees and other policies in-depth promotion, especially in the local collection of more and more industrial background, the figure of multinational pharmaceutical companies also began to appear in the key market list.
January 11, Zhejiang Province announced the results of the selection of some drug centralized band procurement, Eiswei's reberazole sodium, Fesenyuscabi's compound α-ketonic acid tablets, Germany's Losan's bear deoxycholic acid capsules were selected as Group A; Jiangsu Province released the results of the first round of centralized drug procurement, in addition to the aforementioned Fessen Yuscabi compound α-ketonic acid tablets, Losan Pharma GmbH's bear deoxycholic acid, Novartic Pharmaceuticals' Octopide, Minophagen Pharmaceutical Co, Ltd. Zama Factory's compound glyphosate is also on the shortlist as a Group A.
Some people in the industry believe that some provinces and cities in the volume procurement rules no longer take the form of exclusive winning bid, nor is it enough to emphasize price reduction, can allow domestic and original research products at the same time to bid and other initiatives, so that multinational pharmaceutical companies have more motivation to participate.
under the volume procurement policy, the use of most of the patented original drugs that could not be selected will be subject to greater restrictions in the hospital market, which has also prompted some multinational pharmaceutical companies to change their previously tough price-cutting attitudes.
, however, from the current practice, re-planning business model, the transition to retail pharmacies and online channels is still more multinational pharmaceutical companies to choose the strategy.
how these two different corporate strategic trends will continue to evolve in the future remains to be seen.